Claim Ledger
92% answered
Did management answer the analysts?
12 analyst questions audited.
View Claim Ledger →Cipla Ltd — Q1 FY24
Cipla delivered a strong Q1 FY24 with 18% YoY revenue growth to INR 6,329 crore, driven by record performance in India (12% growth) and the US ($222 million, +43% YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla delivered a strong Q1 FY24 with 18% YoY revenue growth to INR 6,329 crore, driven by record performance in India (12% growth) and the US ($222 million, +43% YoY). EBITDA margin expanded to 23.6%, aided by favorable mix and operational efficiencies. PAT stood at INR 996 crore (15.7% of sales). The US complex portfolio, including Lanreotide (18% market share) and stabilized Albuterol, powered growth, while India's chronic share rose to 60%. Management raised full-year EBITDA margin guidance to ~23% (from 22% earlier). Key pipeline catalysts include Symbicort filing by year-end, 4-5 peptide launches over two years, and de-risking of Advair and Abraxane. Risks include US FDA classification for Indore facility and potential pricing pressure in the US generics market.
सिप्ला ने पहली तिमाही में शानदार प्रदर्शन किया। कंपनी की कमाई पिछले साल से 18% बढ़कर 6,329 करोड़ रुपये हो गई। भारत में बिक्री 12% और अमेरिका में 43% बढ़ी। कंपनी का मुनाफा 996 करोड़ रुपये रहा। अमेरिका में लैनरियोटाइड दवा की बाजार हिस्सेदारी 18% है। भारत में पुरानी बीमारियों की दवाओं की हिस्सेदारी 60% हो गई। कंपनी ने पूरे साल के लिए मुनाफा मार्जिन का लक्ष्य 23% रखा है। आने वाले समय में नई दवाएं लॉन्च होंगी। जोखिम में अमेरिकी नियामक की जांच और दवाओं की कीमतों में कमी शामिल है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
US FDA classification for Indore facility pending
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Revenue
$222M
+43% YoY
Highest ever quarterly US revenue, driven by differentiated portfolio including Lanreotide and base business growth.
India Chronic Share
60%
+2pp YoY
Chronic therapies now 60% of India branded prescription revenue, up from 58% last year.
Foracort Growth
27%
+27% YoY
Leading inhaler brand Foracort grew 27% in Q1, among fastest in top 10 IPM brands.
Lanreotide Market Share
18%
N/A
Lanreotide market share improved to 18% as per MAT May 2023, up from prior levels.
Fast read
Guidance and risk preview
Management raised FY24 EBITDA margin guidance to approximately 23%, up from earlier 22% guidance, driven by strong Q1 performance and confidence ac...
Cipla awaits US FDA classification for its Indore facility, which was audited in February 2023.
View Risks →